Cladribine for treating relapsing multiple sclerosis ID6263Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 February 2025
Evobrutinib for treating relapsing multiple sclerosis [ID6313]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis TS ID 11895Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ublituximab for treating relapsing–remitting multiple sclerosis ID6350Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC